Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,394 result(s) found. Displaying page 2,046 of 2,220.
    «« First « Previous 2042  2043  2044  2045  2046  2047  2048  2049  2050  Next» Last»»
    EudraCT Number: 2015-004535-12 Sponsor Protocol Number: KO-TIP-001 Start Date*: 2016-02-25
    Sponsor Name:Kura Oncology, Inc.
    Full Title: An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations
    Medical condition: Advanced Non-Hematological Malignancies with HRAS mutations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    18.1 10018065 - General disorders and administration site conditions 10071971 H-ras gene mutation PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005727-80 Sponsor Protocol Number: EMPA Start Date*: Information not available in EudraCT
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: Effect of insulin on renal maximum glucose transport capacity: interaction with empagliflozin. A not randomized pilot study.
    Medical condition: Patients with diabetes mellitus type 2
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002147-15 Sponsor Protocol Number: 200200 Start Date*: Information not available in EudraCT
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DI MANTOVA
    Full Title: Intravenous immunoglobulin for Unverricht–Lundborg disease: single-patient trial.
    Medical condition: Unverricht-Lundborg disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10054858 Unverricht's syndrome LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10054895 Baltic myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054894 Unverricht-Lundborg disease LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000212-16 Sponsor Protocol Number: HYKS-190116 Start Date*: 2016-04-12
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Hydrocortisone vs. pasireotide in preventing pancreatic fistula and other complications after pancreatic resection - a prospective, randomized, controlled trial
    Medical condition: Patients undergoing pancreatic resection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-003921-51 Sponsor Protocol Number: BOT112-03 Start Date*: 2021-02-11
    Sponsor Name:Highlight Therapeutics
    Full Title: Phase 2 single arm clinical study to evaluate the efficacy and safety of intratumoral administration of BO-112 in combination with pembrolizumab in subjects that have progressed on anti-PD-1-based ...
    Medical condition: Advanced melanoma after progression to immunotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027155 Melanoma skin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001537-24 Sponsor Protocol Number: EMR100070-005 Start Date*: 2015-12-14
    Sponsor Name:Merck KGaA
    Full Title: A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based doublet as a first line treatment of recurrent or Stage IV PD L1+ non small cell lung cancer
    Medical condition: First Line Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) PT (Completed) LT (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) HU (Completed) PL (Completed) NL (Completed) FR (Completed) DK (Completed) BG (Completed) HR (Completed) CY (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012260-14 Sponsor Protocol Number: 20050418 Start Date*: 2010-08-27
    Sponsor Name:Department of Endocrine Oncology
    Full Title: An open, non-randomized phase-2 study of efficacy and safety of treatment with 177Lutetium-DOTA0-Tyr3-octreotate in patients with neuroendocrine tumors
    Medical condition: Patients with malignant neuroendocrine tumours, not amenable to surgical treatment or radiofrequency ablation. Renal, bone marrow and liver function must be sufficient.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007384-17 Sponsor Protocol Number: 3005099 Start Date*: 2009-11-30
    Sponsor Name:Sten Walther
    Full Title: A prospective, multi-centre, randomised, double-blind, placebo-controlled comparison of intravenous dexmedetomidine with haloperidol in treatment of hyperactive delirium after heart surgery.
    Medical condition: Postoperative hyperactive delirium
    Disease: Version SOC Term Classification Code Term Level
    12.0 10000702 Acute delirium LLT
    12.0 10049989 Agitation postoperative LLT
    12.0 10056436 Psychomotor agitation LLT
    12.0 10049987 Confusion postoperative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001630-18 Sponsor Protocol Number: CWL15001 Start Date*: 2023-09-20
    Sponsor Name:5med GmbH
    Full Title: A randomized, parallel group, multi-center study of a fentanyl nasal spray compared with placebo nasal spray for postoperative pain management and prolonged open treatment over up to 120 hours post...
    Medical condition: Management of pain following orthopedic surgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036236 Postoperative pain relief LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005754-80 Sponsor Protocol Number: STING 2 Start Date*: 2007-10-15
    Sponsor Name:Karolinska University Hospital [...]
    1. Karolinska University Hospital
    2. Swedish Lung Cancer Group
    3.
    Full Title: Standard treatment compared to intensified treatment with pegfilgrastim support in patients with small-cell lung cancer, limited disease. A phase III study.
    Medical condition: Small Cell Lung Cancer (limited disease)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000374-37 Sponsor Protocol Number: 161505 Start Date*: 2016-10-28
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculone...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NO (Completed) GR (Completed) SK (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001997-41 Sponsor Protocol Number: 20170122 Start Date*: 2018-05-24
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide, with and without Dexa...
    Medical condition: Subjects with pathologically documented relapsed/ refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002766-50 Sponsor Protocol Number: ProTrans-T1D Start Date*: 2017-10-12
    Sponsor Name:NextCell Pharma
    Full Title: A DOUBLE-BLINDED, RANDOMIZED, PARALLEL, PLACEBO-CONTROLLED TRIAL OF WHARTON’S JELLY DERIVED ALLOGENEIC MESENCHYMAL STROMAL CELLS TO PRESERVE ENDOGENOUS INSULIN PRODUCTION IN ADULT PATIENTS DIAGNOSE...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012594 Diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004264-19 Sponsor Protocol Number: NEODEX2 Start Date*: 2017-04-05
    Sponsor Name:Uppsala County Council
    Full Title: Anesthesia with dexmedetomidine and fentanyl for neonatal surgery. A pilot study.
    Medical condition: The state of anesthesia intraoperatively and pain postoperatively
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003275-22 Sponsor Protocol Number: NEODEX1 Start Date*: 2016-12-14
    Sponsor Name:Uppsala County Council
    Full Title: Evaluation of the analgesic and sedative effects of dexmedetomidine for neonatal peripheral vein cannulation
    Medical condition: Pain on i v cannulation
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003784-68 Sponsor Protocol Number: 4 Start Date*: 2005-04-05
    Sponsor Name:University Hospital Bern
    Full Title: Subcutanoeus Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients with Coroanry Artery Disease (FILCAD)
    Medical condition: Coronary Artery Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021061-72 Sponsor Protocol Number: 103462 Start Date*: 2011-01-03
    Sponsor Name:Ögonkliniken, Akademiska sjukhuset i Uppsala
    Full Title: To evaluate the safety and efficacy of a single subconjunctival injection of methylprednisolone versus standard postoperative steroid regiment in terms of intraocular inflammation and intraocular p...
    Medical condition: Att studera säkerheten och effekten av en engångs subkonjunktival injektion med metylprednisolon jämfört med sedvanliga postoperativa kortisonbehandling med ögondroppar avseende intraokulär tryckst...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023560-40 Sponsor Protocol Number: STU00010022 Start Date*: 2011-03-23
    Sponsor Name:Uppsala l�ns landsting
    Full Title: Haematopoetic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004293-33 Sponsor Protocol Number: RPC01-3202 Start Date*: 2018-03-06
    Sponsor Name:Celgene International II Sàrl
    Full Title: Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) LT (Completed) DE (Completed) FR (Completed) SI (Completed) AT (Completed) BG (Completed) GR (Completed) ES (Completed) SE (Completed) NL (Completed) PL (Completed) PT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-004040-29 Sponsor Protocol Number: CY5031 Start Date*: Information not available in EudraCT
    Sponsor Name:Cytokinetics Inc
    Full Title: A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS).
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2042  2043  2044  2045  2046  2047  2048  2049  2050  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 29 16:47:51 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA